Watchlist Price Alert

C4 Therapeutics Inc. (CCCC)

NASDAQ: CCCC · Real-Time Price · USD

1.45

-0.09 (-5.84%)

At close: May 09, 2025, 3:59 PM

1.50

3.45%

After-hours: May 09, 2025, 05:50 PM EDT

-5.84% (1D)

Bid	1.44
Market Cap	102.96M
Revenue (ttm)	35.58M
Net Income (ttm)	-105.32M
EPS (ttm)	-1.52
PE Ratio (ttm)	-0.95
Forward PE	n/a
Analyst	Buy

Ask	1.71
Volume	988,553
Avg. Volume (20D)	1,251,111
Open	1.53
Previous Close	1.54
Day's Range	1.45 - 1.63
52-Week Range	1.08 - 7.66
Beta	3.11

About CCCC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CCCC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CCCC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

C4 Therapeutics has released their quartely earnings on May 7, 2025:

Revenue of $7.24M exceeds estimates by $4.29M, with 138.17% YoY growth.

EPS of -0.37 exceeds estimates by 0.05, with 9.76% YoY growth.

Why Price Moved

8 months ago

+13.79%

C4 Therapeutics shares are trading higher after th... Unlock content with Pro Subscription

News

2 days ago · zacks.com

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.41 per share a year ago.

2 months ago · zacks.com

C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings est...

2 months ago · zacks.com

C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for C4 Therapeutics (CCCC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana...

2 months ago · zacks.com

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago.

2 months ago · zacks.com

C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner